The TBCRC-056 trial showed a 50% pCR rate in TNBC patients with BRCA or PALB2 mutations treated with niraparib and dostarlimab. sTILs increased significantly in both treatment arms, with higher ...
Early and sustained ctDNA clearance in early breast cancer treated with neoadjuvant HER2-targeted therapy tracks closely with pathologic complete response to treatment and 3-year outcomes.
Retreatment with pemetrexed-based chemotherapy (PBC) in patients with malignant pleural mesothelioma (MPM): An observational study. Background: Tumors shed DNA into the blood stream and the plasma DNA ...
MedPage Today on MSN
Preop RT May Boost Response to Chemo-Immunotherapy in High-Risk Early Breast Cancer
SAN ANTONIO -- Preoperative radiotherapy (RT) plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune ...
Adjuvant capecitabine treatment for stage III colon cancer in Japanese patients (KSCC0803). Phase II trial of cetuximab plus irinotecan for FOLFOX and FOLFIRI-refractory patients with EGFR-positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback